Therapeutic Asset Ratings
435 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Eloxatin
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer Institute
P2/3
BBB
(78)
Irinotecan
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer Institute
P2/3
BBB
(78)
Inno-206
Hematopoietic And Lymphoid System Neoplasm
OHSU Knight Cancer Institute
P4
BBB
(76)
Cyclophosphamide
Anemia
OHSU Knight Cancer Institute
P4
BBB
(73)
Letrozole
Breast Carcinoma
OHSU Knight Cancer Institute
P4
BBB
(73)
Letrozole
Breast Carcinoma
OHSU Knight Cancer Institute
P4
BBB
(73)
Ruxolitinib
Primary Myelofibrosis
OHSU Knight Cancer Institute
P4
BBB
(73)
Irinotecan
Ovarian Carcinoma
OHSU Knight Cancer Institute
P2
BB
(71)
Letrozole
Stage III Pancreatic Cancer AJCC v8
OHSU Knight Cancer Institute
P2
BB
(71)
Daunorubicin
Myelodysplastic Syndrome
OHSU Knight Cancer Institute
P3
BB
(70)
Irinotecan
Breast Carcinoma
OHSU Knight Cancer Institute
P3
BB
(70)
Vinorelbine
Recurrent Ovarian Carcinoma
OHSU Knight Cancer Institute
P2
BB
(70)
Carboplatin
Myelodysplastic/Myeloproliferative Neoplasm
OHSU Knight Cancer Institute
P2/3
BB
(70)
Bortezomib
Hematopoietic And Lymphoid System Neoplasm
OHSU Knight Cancer Institute
P4
BB
(69)
Idarubicine
Myelodysplastic Syndrome
OHSU Knight Cancer Institute
P4
BB
(69)
Casodex
Prostate Adenocarcinoma
OHSU Knight Cancer Institute
P3
BB
(69)
(+)-VINCRISTINE
Stage IV Breast Cancer
OHSU Knight Cancer Institute
P3
BB
(69)
Azacitidine
Acute Monocytic Leukemia
OHSU Knight Cancer Institute
P2
BB
(69)
Rapamycin
Myelodysplastic/Myeloproliferative Neoplasm
OHSU Knight Cancer Institute
P2
BB
(69)
Atezolizumab
Ovarian Carcinoma
OHSU Knight Cancer Institute
P3
BB
(68)
DEXAMETHASONE
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
OHSU Knight Cancer Institute
P2
BB
(68)
Eloxatin
Soft Tissue Sarcoma
OHSU Knight Cancer Institute
P2
BB
(68)
Gdc-0449
Exocrine Pancreatic Carcinoma
OHSU Knight Cancer Institute
P2
BB
(68)
Ipilimumab
Recurrent Non-Hodgkin Lymphoma
OHSU Knight Cancer Institute
P2
BB
(68)
(+)-VINCRISTINE
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
OHSU Knight Cancer Institute
P2
BB
(68)
Showing 1 to 25 of 435 assets
Previous
Page 1 of 18
Next